Panacea-ml develops a machine learning-based software system that utilizes predictive analytics to enhance patient selection and trial design for clinical studies in diseases such as ALS, diabetes, and cancer. The platform reduces trial duration and costs while increasing the likelihood of successful market approval for new treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Clinical trials often face challenges in patient selection, leading to increased trial duration, higher costs, and a greater risk of failure in bringing new treatments to market. Identifying the right patient profiles and predicting potential adverse effects remains a significant hurdle for pharmaceutical companies and CROs.
Solution
Panacea-ml offers a SaaS AI system that leverages machine learning and predictive analytics to optimize patient selection and trial design for clinical studies. The platform analyzes historical patient data and real-world electronic health records to identify ideal trial participants and predict potential adverse side effects. By providing high-value insights, Panacea-ml enables pharmaceutical companies and CROs to design and execute clinical trials more efficiently, reducing the risk of failure and accelerating the delivery of effective treatments to market. The system's user-friendly interface is customized to the client and is disease and treatment agnostic.
Target Audience
The primary customers are pharmaceutical companies and contract research organizations (CROs) seeking to improve the efficiency and success rates of their clinical trials.
Features
- AI-driven analysis of historical patient data to identify optimal trial participants.
- Predictive analytics to minimize safety risks and improve patient retention.
- Identification of novel marker-endpoint interrelations and causal relationships.
- Customizable, user-friendly SaaS interface.
- Disease and treatment agnostic platform applicable to various therapeutic areas.
- Collaboration tools to enhance teamwork across development teams.